Efficacy and Safety of Didanosine (ddI) and Tenofovir (TDF) Combination as NRTI Backbone of Highly Active Antiretrovirai Treatment (HAART). (24 wk Preliminary Results from Recover Study).

摘要

Due to the complexity of ARV regimens, PK interactions have to be taken into account. Recently, a pharmacokinetic interaction between TDF and didanosine has been described. The clinical relevance of this interaction has to be established. Recover is an observational, prospective, multicenter switch study in which subjects who started TDF treatment due to any NRTI associated toxicity were recruited to follow the evolution of this adverse effect. Here, we analyze the evolution in terms of safety and efficacy of those subjects who, after the switching, are on a TDF plus ddI based regimen. Our data gives us to conclude that TDF plus ddI based regimens are safe and efficacious in this kind of patients.